ESTUDIO DE FASE 3, ALEATORIZADO, ABIERTO, DE LORLATINIB (PF-06463922) EN MONOTERAPIA VERSUS CRIZOTINIB EN MONOTERAPIA EN EL TRATAMIENTO DE PRIMERA LÍNEA DE PACIENTES CON CÁNCER DE PULMÓN DE CÉLULAS NO PEQUEÑAS AVANZADO ALK-POSITIVO

Activo, no reclutaFase 3ClinicalTrials.gov

ID: NCT03052608Tipo: INTERVENTIONALInicio: 27 de abr de 2017Fin estimado: 31 de dic de 2028

Resumen

Estudio de fase 3 para demostrar si lorlatinib administrado en monoterapia es superior a crizotinib solo en prolongar la supervivencia libre de progresión en pacientes con CPNCP avanzado ALK-positivo sin tratamiento previo, y para comparar lorlatinib con crizotinib en cuanto a la supervivencia global en la misma población.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Histologically or cytologically confirmed diagnosis of locally advanced or metastatic ALK-positive NSCLC; at least 1 extracranial measurable target lesion not previously irradiated. CNS metastases allowed if asymptomatic and not currently requiring corticosteroid treatment.
Availability of an archival FFPE tissue specimen.
No prior systemic NSCLC treatment.
ECOG PS 0, 1, or 2.
Age ≥18 years .
Adequate Bone Marrow, Liver, Renal, Pancreatic Function
Negative pregnancy test for females of childbearing potential

Criterios de exclusión

Spinal cord compression unless good pain control attained
Major surgery within 4 weeks prior to randomization.
Radiation therapy within 2 weeks prior to randomization, including stereotactic or partial brain irradiation. Whole brain irradiation within 4 weeks prior to randomization
Active bacterial, fungal, or viral infection
Clinically significant cardiovascular disease, active or within 3 months prior to enrollment. Ongoing cardiac dysrhythmias, uncontrolled atrial fibrillation, bradycardia or congenital long QT syndrome
Predisposing characteristics for acute pancreatitis in the last month prior to randomization.
History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease
Active malignancy (other than NSCLC, non melanoma skin cancer, in situ cervical cancer, papillary thyroid cancer, LCIS/DCIS of the breast, or localized prostate cancer) within the last 3 years prior to randomization.
Concurrent use of any of the following food or drugs within 12 days prior to the first dose of lorlatinib or crizotinib.
known strong CYP3A inhibitors .
known strong CYP3A inducers
known P gp substrates with a narrow therapeutic index
Concurrent use of CYP3A substrates with narrow therapeutic indices within 12 days prior to the first dose of lorlatinib or crizotinib.
Other severe acute or chronic medical or psychiatric condition, including recent or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or interfere with the interpretation of study results
Investigational site staff members directly involved in the conduct of the study and their family members, or Pfizer employees, including their family members, directly involved in the conduct of the study.
Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation.

Intervenciones

drug

Lorlatinib

ALK-positive NSCL treatment

drug

Crizotinib

ALK-positive NSCL treatment

Ubicaciones

Centro de Investigacion Pergamino SA

Pergamino, Buenos Aires, Argentina

Centro Medico Austral

CABA, Argentina

Patrocinadores

PrincipalPfizer

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

ESTUDIO DE FASE 3, ALEATORIZADO, ABIERTO, DE LORLATINIB (... | EligiMed